June 1, 2016
Today, Gubra announced a change in its executive management team. In order to continue to stay focused on high scientific standards and to accommodate strong growth going forward in both its client base and revenue, Gubra has appointed CBO Henrik Blou as new CEO. In addition, Gubra has appointed Jan K. Villadsen as new CFO. Co-founder and current CEO Niels Vrang will continue full time in the company, but focus on client relations, science and innovation. Gubra has experienced significant growth in revenue and customer base in 2015, a large increase in the number of employees over the past 12 months, as well as a recent move to new facilities.
Niels Vrang emphasized the importance of this organizational adjustment: “Today we have more than 65 employees at Gubra and we feel that the time has come to boost the executive management team while maintaining scientific excellence. Henrik Blou has shown a thorough understanding of Gubra and at the same time impressed us with his ability to make things happen. I – for my part – will now be able to focus on scientific and business interactions with our customers and internally. It is a natural move – just a matter of finding the right time”.
”Gubra is in a very interesting position: We are attracting a lot of talented and enthusiastic people and we are growing on almost all parameters”, Henrik Blou says. “I am very grateful that I am offered this opportunity – it is an honor to be selected to lead Gubra into the next era”.
Contacts
Sofia Pitt Boserup
Lead Communication Partner
+45 41889586
sbo@gubra.dk
About Gubra
Gubra is a privately held biotech company since 2008, headquartered in Denmark. The company is a science and technology driven company with two primary areas of business: Preclinical contract research services (CRO) and proprietary early target and drug discovery programs. Gubra’s primary focus is within the metabolic space (obesity, diabetes, NASH, CKD, CVD and diabetic complications) adding to this fibrotic disease areas such as IPF and IBD. Gubra specializes in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, 3D imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. High quality, scientific excellence, advanced digitalization, speed and solid teamwork, are key company traits which have established Gubra as a highly professional and competent partner in the market. Learn more at www.gubra.dk
The post Gubra announces changes to executive management team appeared first on Gubra.
